Alimta Mesothelioma Pemetrexed Treatment

Traditional Mesothelioma Treatment

Mesothelioma Peritoneal Treatment

Radical Mesothelioma Treatment

2 Interleukin Malignant Mesothelioma Treatment

Mesothelioma Treatment Option

Alternative Mesothelioma Treatment

New Mesothelioma Treatment

Mesothelioma Treatment Info:

Please use the links to the left for more specific information on Mesothelioma Treatment. The links to the right are sponsored links.

Mesothelioma Clinical Trials

Mesothelioma clinical trials are studies of new treatments in patients. These treatments are most often new chemotherapy drugs, or sometimes surgery in combination with a drug treatment. Researchers perform a clinical trial when there is some reason to believe that the treatment under evaluation may aid patients. In general researchers perform clinical trials to determine whether a treatment works, whether it is more effective then existing treatments, whether the side effects are too severe to justify the treatments use, and which patients benefit most from the treatment. At any given time, there are usually between 15 to 20 active clinical trials throughout the world investigating new therapies for mesothelioma. Researchers are conducting more than half of those trials in the United States.

While being treated for mesothelioma, a doctor may suggest that a patient look into a clinical trial. Though this does not mean that the patient has no other hope, the patient should be aware of the risks associated with clinical trials. No one knows in advance if the treatment will work or exactly what side effects will occur.

Researchers conduct clinical trials in steps called phases. Each phase answers certain questions. Clinical trials are usually classified into one of three phases.

Phase I trials evaluate how doctors should administer a new drug (i.e. by mouth, injected into the blood, or injected into the muscle), how often, and at what dose. A Phase I trial usually enrolls only a small number of patients, sometimes as few as a dozen.

Phase II trials continue to test the safety of the drug, and begin to evaluate how well the new drug works. Phase II studies usually narrow the focus to a particular type of cancer.

Phase III trials test a new drug, a new combination of drugs, or a new surgical procedure compared to the current standard therapy. Researchers assign participants to the standard group or the new group at random. Phase III trials often enroll large numbers of people and may be conducted at many doctors' offices, clinics, and cancer centers nationwide.

The benefit of participating in a clinical trial is that a patient can receive a treatment that the U.S. Food and Drug Administration has yet to approve and they may be of substantial benefit. Additionally studies have shown that mesothelioma patients that participate in clincial trials tend to live longer and received better care than those who do not partcipate.
 

Mesothelioma Clinical Trials that are Currently Recruiting:
Below is a list of new medical treatments for mesothelioma that are undergoing study as part of clinical trials.

1) Expanded Access Study of ALIMTA (pemetrexed) alone or in Combination with Cisplatin for Patients with Malignant Pleural and Peritoneal Mesothelioma.
Read more about Alimta >>

2) Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
Patient Conditions as part of the study include: localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma and epithelial mesothelioma.

3) Mesothelioma Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
Conditions as part of the study include: localized malignant mesothelioma; recurrent malignant mesothelioma; epithelial mesothelioma; sarcomatous mesothelioma

4) Mesothelioma Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
Conditions as part of the study include: localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma

5) Doxorubicin With or Without P-30 Protein in Treating Patients With Mesothelioma
Conditions as part of the study include: localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma

6) Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Conditions: advanced malignant mesothelioma; recurrent malignant mesothelioma; epithelial mesothelioma; sarcomatous mesothelioma

7) Pemetrexed Disodium and Gemcitabine in Treating Patients With Mesothelioma
Conditions: advanced malignant mesothelioma; epithelial mesothelioma; sarcomatous mesothelioma.
Read more about Pemetrexed Disodium >>

8) Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Conditions: localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma.

9) Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Conditions: advanced malignant mesothelioma; recurrent malignant mesothelioma

10) Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma
Conditions: localized malignant mesothelioma; advanced malignant mesothelioma; perioperative/postoperative complications.

11) Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung
Condition: localized malignant mesothelioma

12) Mesothelioma Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
Conditions: localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma

13) Experimental Drug SS1(dsFv)-PE38 to Treat Cancer
Conditions: Mesothelioma; Ovarian Neoplasm; Squamous Cell Neoplasm.

14) Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Patients with Pulmonary and Pleural Malignancies
Conditions: Small Cell Carcinoma; Mesothelioma; Non-Small-Cell Lung Carcinoma.

15) Treatment of Peritoneal Cancer with Surgery, Perfused Heated Cisplatin, and Chemotherapy
Conditions: Abdominal Neoplasm; Colonic Neoplasm; Mesothelioma; Peritoneal Neoplasm.

16) Study of Decitabine in Preventing Tumor Growth
Conditions: Esophageal Cancer; Lung Neoplasm; Mesothelioma.

17) Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
Conditions: adult primary liver cancer; adult soft tissue sarcoma; Brain Tumor; childhood liver cancer; childhood soft tissue sarcoma; Thyroid Cancer.

18) Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Conditions: recurrent non-small cell lung cancer; Recurrent Small Cell Lung Cancer; recurrent malignant mesothelioma; recurrent malignant thymoma; ...

19) Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Conditions: Bladder Cancer; Brain Tumor; Breast Cancer; Cervical Cancer; Colon Cancer; Esophageal Cancer; Lung Cancer; ovarian epithelial cancer; ...

20) PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
Conditions: adult primary liver cancer; Bladder Cancer; Colon Cancer; Endometrial Cancer; Gastric Cancer; Liver Cancer; Lymphoma; ovarian epithelial cancer; ...

21) Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
Conditions: Brain Tumor; Breast Cancer; Colon Cancer; Lung Cancer; Melanoma; Pancreatic Cancer; Renal Cell Cancer

22) Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
Condition: Neoplasms

23) Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
Condition: Neoplasms

24) Not yet recruiting
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Conditions in study will be: advanced malignant mesothelioma; epithelial mesothelioma; recurrent malignant mesothelioma; sarcomatous mesothelioma.